中文名称: UNBS5162  一键复制产品信息
英文名称: UNBS5162
CAS No: 956590-23-1
分子式: C17H18N4O3
分子量: 326.35
U10068 UNBS5162 ≥98% (普西唐-psaitong)
包装规格:
1mg 5mg 10mg 25mg 50mg 100mg in glass bottle
溶解性:
溶于DMSO(21.5 mg/mL 超声,加热)
产品描述:

基本信息

产品编号:

U10068 

产品名称:

UNBS5162

CAS:

956590-23-1

 

储存条件

粉末

-20℃

四年

 

 

分子式:

C17H18N4O3

溶于液体

-80℃

6个月

分子量

326.35

-20℃

1个月

化学名: 

1-(2-(2-(dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea

Solubility (25°C):

 

体外:

 

DMSO

17mg/mL (52.09mM)

Ethanol

Insoluble

Water

Insoluble

体内(现配现用):

 

1mg/ml表示微溶或不溶。

普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。

 

制备储备液

 

浓度

 

溶液体积

质量

 

1mg

 

5mg

 

10mg

1mM

3.0642mL

15.3210mL

30.6419mL

5mM

0.6128mL

3.0642mL

6.1284mL

10mM

0.3064mL

1.5321mL

3.0642mL

50mM

0.0613mL

0.3064mL

0.6128mL

 

生物活性

产品描述

一种广谱的趋化因子配体 CXCL 拮抗剂,具有抗肿瘤活性。

靶点

CXC

 

体外研究

UNBS5162 is a pan-antagonist of CXCL chemokine expression and exhibits weak antiproliferative activity against human cancer cell lines with mean IC50 of 17.9µM.UNBS5162 markedly impairs PC-3 tumor cell growth kinetics,without inducing senescence,whereas the reverse feature is observed with respect to DU-145 cells.UNBS5162 is cytotoxic to a range of human cancer cell lines including glioblastoma (Hs683 and U373MG),colorectal (HCT-15 and LoVo),non-small-cell lung (A549) and breast (MCF-7),with IC50s of 0.5-5µM.UNBS5162 also markedly increases the levels of expression of LC3-I and LC3-II in human cancer cells. UNBS5162 displays no anti topoisomerase II activity. Moreover,UNBS5162 induces cancer cell death through lysosomal membrane permeabilization (LMP) in PC3 prostate cancer cells but not in U373 glioblastoma cells,with this LMP process occurring as an UNBS5162-induced decrease in Hsp70 expression.UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signaling pathway.UNBS5162 downregulates the protein expression of proteins associated with the PI3K/AKT signaling pathway, including the levels of phosphorylated (p)-AKT,p-mechanistic target of rapamycin kinase,ribosomal protein S6 kinaseβ1 and cyclin D1.

体内研究

UNBS5162 (20mg/kg,i.v.) increases the therapeutic benefits of taxol in vivo in the orthotopic human PC-3 prostate cancer model.

 

推荐实验方法(仅供参考)

细胞实验:

 

细胞系

PC-3和DU-145细胞

浓度

10µM

处理时间

72h

 

动物实验:

 

Mice

Orthotopic xenografts are obtained by injecting 2.5×106 human PC-3 or DU-145 cells into the prostate of 6-week-old male nu/nu mice (n=9 animals per treatment group).All grafts are performed under anesthesia [saline/Rompun/Imalgene;5:1:1 by volume].The end point in these orthotopic experiments is the survival period of the tumor-bearing mice after the administration of UNBS3157,UNBS5162,or reference anticancer agents (taxol,mitoxantrone, and amonafide).However,for ethical reasons,animals are killed when 20% of body weight have been lost compared to that determined at the time of tumor grafting.All animals are weighed three times a week.Autopsies and histologic diagnoses are performed on each mouse to confirm the presence of tumor development; 100% is achieved.In the case of UNBS5162 experiments in the PC-3 model,after the sacrifice of animals,tumors are removed from both drug-treated [10mg/kg,intravenous (i.v.)] and vehicletreated mice,fixed in buffered formalin,embedded in paraffin,and 5-µm-thick sections taken.These histologic slides are then stained with hematoxylin and eosin for blood vessel counts.

 

保存条件:
-20℃
UN码:
HazardClass:
危害声明:
安全说明:
搜索质检报告(COA)

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • =
    *
    *
    *选择对应的单位 *空出希望得到的变量,填写另外两个变量

用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )

  • * = *

连续稀释计算器方程

  • 连续稀释

  • 初始浓度:
  • 稀释倍数:
  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
请在下列方框中输入相关信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
举例:给药剂量是10 mg/kg,每只动物体重20g,给药体积100 μL, TargetMol | Animal experiments  一共给药动物10只,您使用的配方为5%TargetMol | reagent DMSO 30%PEG300 5%Tween 80 60%Saline/PBS/ddH2O, 那么您的工作液浓度为2mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent  ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们客服联系。
体内配方的制备方法: 取 50μLDMSOTargetMol | reagent  母液,添加 300 μLPEG300TargetMol | reagent  混匀澄清,再加 50μLTween80, 混匀澄清,再加 600μLSaline/PBS/ddH2OTargetMol | reagent ​ 混匀澄清

方案所需的各种助溶剂如: DMSO , PEG300 / PEG400 , Tween 80 , SBE-β-CD , 玉米油 等, 均可点击跳转或在网站搜索购买。
 
以上为“动物实验计算换算器”的使用方法举例,并不是具体某个试剂的配制,请根据您的实验动物和给药方式选择适当的溶解方案。
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系普西唐客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度 mg/ml;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多